References of "CAERS, Jo"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDiagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
CAERS, Jo ULg; Vekemans, Marie-Christiane; Bries, Greet et al

in Annals of Medicine (2013), 45

The prevalence of monoclonal gammopathy of undetermined significance (MGUS) is generally estimated at 3.4% in the general population over 50 years, and its incidence increases with age. MGUS represents a ... [more ▼]

The prevalence of monoclonal gammopathy of undetermined significance (MGUS) is generally estimated at 3.4% in the general population over 50 years, and its incidence increases with age. MGUS represents a preneoplastic entity that can transform into multiple myeloma or other lymphoproliferative disorders. The risk of malignant transformation is estimated at 1% per year and persists over time. Predictors of malignant transformation have been identified such as the heavy chain isotype, the monoclonal component level, increasing levels of M-protein during the first years of follow-up, bone marrow plasmocytosis, dosage of serum free light chains, the presence of immunophenotypic abnormal plasma cells, aneuploidy and the presence of circulating plasma cells. Prognostic scores that combine certain of these factors have been proposed and allow the identification of high-risk patients. Their use could assist in tailoring the care for each patient, based on his/her risk profile. [less ▲]

Detailed reference viewed: 32 (7 ULg)
Full Text
Peer Reviewed
See detailPlasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea, C; Kyle, RA; Durie, BG et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2013), 27(4), 780-91

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailA novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).
JASPERS, Aurélie ULg; CAERS, Jo ULg; LE GAC, Gerald et al

in British Journal of Haematology (2013), 160(4), 564-565

Detailed reference viewed: 26 (12 ULg)
Full Text
Peer Reviewed
See detailImage of the month: Hairy kidneys
Cornet, G; GRAYET, Benjamin ULg; Godon, A et al

in Revue Médicale de Liège (2013), 68(1), 4-5

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailGammapathies monoclonales de signification indéterminée
Vekemans, Marie-Christiane; CAERS, Jo ULg; Doyen, Chantal et al

in Louvain Medical (2013), 132(2), 51-62

Detailed reference viewed: 12 (3 ULg)
Full Text
Peer Reviewed
See detailUnexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis.
DE PASQUAL, Aurelie ULg; BIESSAUX, Yves ULg; Blettard, Noelle et al

in Acta Clinica Belgica (2013), 68(4), 303-305

Detailed reference viewed: 16 (6 ULg)
Peer Reviewed
See detailErdheim-Chester Disease : A Monocentric Series Of 96 Patients
Haroche, Julien; Arnaud, Laurent; Cohen-Aubart, Fleur et al

Poster (2013)

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailBone mass of the calvarium
SIMONI, Paolo ULg; STULKO, Jennifer ULg; BEN MUSTAPHA, Selma ULg et al

in Skeletal Radiology (2013), 42

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailAspects biologiques de l'angiogenèse dans le myélome multiple
Otjacques, Eléonore ULg; Binsfeld, Marilène ULg; Beguin, Yves ULg et al

in Oncohématologie (2013), 7(2), 6-12

Le myélome multiple (MM) est une maladie hématologique caractérisée par la prolifération excessive de plasmocytes cancéreux au sein de la moelle osseuse. Une des caractéristiques principales de cette ... [more ▼]

Le myélome multiple (MM) est une maladie hématologique caractérisée par la prolifération excessive de plasmocytes cancéreux au sein de la moelle osseuse. Une des caractéristiques principales de cette maladie est l’interaction entre les cellules myélomateuses et les cellules voisines situées dans la moelle. De par l’activation des cellules endothéliales, l’angiogenèse joue un rôle essentiel dans le développement du MM. Dans cet article, les processus permettant la progression du phénomène d’angiogenèse dans le MM seront abordés. Entre autres, nous identifierons les cellules interagissant avec les plasmocytes cancéreux, les cytokines influençant l’angiogenèse ou encore les protéases responsables de la dégradation de la matrice extracellulaire impliquées dans la pathologie. Finalement, l’influence du phénomène d’hypoxie (via l’expression de la protéine hypoxia-inducible factor-1) et le rôle de l’activation constitutive du Nuclear Factor-kB dans la néovascularisation seront mis en avant. [less ▲]

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailMithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors.
Otjacques, Eléonore ULg; Binsfeld, Marilène ULg; Rocks, Natacha ULg et al

in PLoS ONE (2013), 8(5), 62818

Mithramycin (MTM), a cytotoxic compound, is currently being investigated for its anti-angiogenic activity that seems to be mediated through an inhibition of the transcription factor SP1. In this study we ... [more ▼]

Mithramycin (MTM), a cytotoxic compound, is currently being investigated for its anti-angiogenic activity that seems to be mediated through an inhibition of the transcription factor SP1. In this study we evaluated its anti-myeloma effects in the syngenic 5TGM1 model in vitro as well as in vivo. In vitro, MTM inhibited DNA synthesis of 5TGM1 cells with an IC50 of 400 nM and induced an arrest in cell cycle progression at the G1/S transition point. Western-blot revealed an up-regulation of p53, p21 and p27 and an inhibition of c-Myc, while SP1 remained unaffected. In rat aortic ring assays, a strong anti-angiogenic effect was seen, which could be explained by a decrease of VEGF production and an up-regulation of anti-angiogenic proteins such as IP10 after MTM treatment. The administration of MTM to mice injected with 5TGM1 decreased 5TGM1 cell invasion into bone marrow and myeloma neovascularisation. These data suggest that MTM displays anti-myeloma and anti-angiogenic effects that are not mediated by an inhibition of SP1 but rather through c-Myc inhibition and p53 activation. [less ▲]

Detailed reference viewed: 30 (5 ULg)
Full Text
See detailThe Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution
Binsfeld, Marilène ULg; Otjacques, Eléonore ULg; Hannon, Muriel ULg et al

in Belgian Journal of Hematology (2013), Abstracts book(Supplement of 28th General Meeting of the Belgian Hematological Society), 41

Detailed reference viewed: 13 (6 ULg)
Full Text
See detailRapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice
Belle, Ludovic ULg; Binsfeld, Marilène ULg; DUBOIS, Sophie ULg et al

in Belgian Journal of Hematology (2012), Abstracts book(Supplement of 27th General Meeting of the Belgian Hematological Society), 14

Detailed reference viewed: 7 (6 ULg)